ArticleAddiction science & clinical practice2022
Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Article in Addiction science & clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07148206 (Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Integrating Psychosocial Factors into Artificial Intelligence Models for Predicting Addiction Treatment Outcomes: A Systematic Review.European addiction research · 2026Pooled it
- Cost-Effectiveness of the START Hospital Addiction Consultation Service for Opioid Use Disorder Treatment.JAMA network open · 2026Trial
- Differences in benefits of office based opioid treatment: Secondary analyses across sub-groups in the PROUD randomized controlled implementation trial.Addiction (Abingdon, England) · 2026Trial
- Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.Journal of substance abuse treatment · 2022Trial
- Would we, could we? Measuring attitudinal and capacity barriers to supporting recovery housing residents on medication for opioid use disorder.Journal of substance use and addiction treatment · 2026Article
- Demonstrating the potential for utilizing mobile methadone units to serve medically institutionalized populations in New York State.Journal of substance use and addiction treatment · 2026Article
- Relationship between extended-release buprenorphine adherence and reduced risk of return to use in patients with opioid use disorder: A retrospective claims data analysis.Drug and alcohol dependence reports · 2026Article
- Cascade of Care for Opioid Use Disorder Among Medicaid Beneficiaries.JAMA network open · 2026Article
- Applying machine learning in predicting medication treatment outcomes for opioid use disorder.Journal of substance use and addiction treatment · 2026Article
- "Convenience, Quickness, and Compassion": Experiences of People Involved in the Criminal-Legal System Accessing Medications for Opioid Use Disorder Services From a Mobile Unit in Chicago.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Harm reduction engagement and ongoing opioid use among adults receiving methadone or buprenorphine in Philadelphia.Harm reduction journal · 2026Article
- Subgroup identification of disparities in buprenorphine discontinuation in opioid-use disorder: A Virtual Twins machine learning approach using nationwide United States claims data, 2006-2022.PLOS mental health · 2026Article
- Mobile addiction treatment units: a narrative review.Addiction science & clinical practice · 2025Review
- Predicting treatment retention in medication for opioid use disorder: a machine learning approach using NLP and LLM-derived clinical features.Journal of the American Medical Informatics Association : JAMIA · 2025Article
- Article
- "HEAL together": a randomized, hybrid type 1 effectiveness-implementation trial protocol of a peer-delivered behavioral activation intervention to improve methadone treatment retention.Frontiers in public health · 2025Article
- Commentary on Gregory et al.: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation.Addiction (Abingdon, England) · 2025Article
- Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type.Addiction (Abingdon, England) · 2025Article
- Study Protocol for Pain Self-Management and Patient-Oriented Buprenorphine Dosing for Pain and Retention in Office-Based Opioid Treatment: A Hybrid Type 1, 2 × 2 Factorial Randomized Controlled Trial.Substance use & addiction journal · 2025Article
- Factors associated with medications for opioid use disorder (MOUD) treatment success during the pregnancy and postpartum periods: A scoping review.Drug and alcohol dependence · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMedication treatment for opioid use disorder (OUD) (MOUD; buprenorphine and methadone) reduces opioid use and overdose. Discontinuation of MOUD can quickly lead to relapse, overdose and death. Few persons who initiate MOUD are retained on treatment, thus it is critical to identify factors associated with retention.
methodsEvaluated data was from an ongoing prospective cohort study of adults aged 18 or older with DSM-5 moderate to severe OUD seeking MOUD in the community and followed for 6 months. Participants were considered retained on MOUD through 6 months if they reported taking MOUD at every study interview without discontinuation. A high dose of MOUD was defined as a methadone dose > 85 mg or buprenorphine dose ≥ 16 mg. Multivariable logistic regression was conducted to assess factors associated with 6-month MOUD retention.
resultsA total of 118 participants (73% male, 58% white, 36% with HIV) were included. Buprenorphine was initiated by 58% and 42% started methadone. MOUD retention was 49% and 58% among buprenorphine and methadone, respectively, at 6-months. In adjusted models, a high MOUD dose (OR = 4.71, 95% CI 2.05-10.84) and higher pain interference (OR = 1.59, 95% CI 1.15-2.19) was associated with MOUD retention.
conclusionsAdequate dosing of MOUD leads to improved retention on MOUD. Further, persons with high pain interference at baseline had higher odds of retention on MOUD. Both methadone and buprenorphine have analgesic effects, thus those with high pain interference could have dual benefits of MOUD for treating OUD and pain. Interventions should be tailored to improve adequate MOUD dosing to improve retention on MOUD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.